Community Bank N.A. cut its position in Amgen Inc. (NASDAQ:AMGN) by 0.6% during the first quarter, Holdings Channel reports. The fund owned 8,450 shares of the medical research company’s stock after selling 50 shares during the period. Community Bank N.A.’s holdings in Amgen were worth $1,386,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently made changes to their positions in the company. Thomas J. Herzfeld Advisors Inc. purchased a new stake in shares of Amgen during the fourth quarter worth approximately $102,000. Alpha Omega Wealth Management LLC raised its stake in shares of Amgen by 19.0% in the first quarter. Alpha Omega Wealth Management LLC now owns 625 shares of the medical research company’s stock worth $103,000 after buying an additional 100 shares during the last quarter. Jackson Grant Investment Advisers Inc. raised its stake in shares of Amgen by 0.6% in the first quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock worth $104,000 after buying an additional 4 shares during the last quarter. Focused Wealth Management Inc raised its stake in shares of Amgen by 248.0% in the fourth quarter. Focused Wealth Management Inc now owns 870 shares of the medical research company’s stock worth $127,000 after buying an additional 620 shares during the last quarter. Finally, Signature Estate & Investment Advisors LLC raised its stake in shares of Amgen by 13.6% in the first quarter. Signature Estate & Investment Advisors LLC now owns 794 shares of the medical research company’s stock worth $130,000 after buying an additional 95 shares during the last quarter. Hedge funds and other institutional investors own 78.80% of the company’s stock.

Shares of Amgen Inc. (AMGN) opened at 177.48 on Wednesday. The firm has a 50-day moving average price of $168.06 and a 200 day moving average price of $165.18. The company has a market cap of $130.52 billion, a PE ratio of 16.86 and a beta of 1.36. Amgen Inc. has a 1-year low of $133.64 and a 1-year high of $184.21.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Wednesday, April 26th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.00 by $0.15. The business had revenue of $5.46 billion for the quarter, compared to analyst estimates of $5.60 billion. Amgen had a return on equity of 29.37% and a net margin of 34.42%. The company’s quarterly revenue was down 1.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.90 earnings per share. On average, equities analysts anticipate that Amgen Inc. will post $12.46 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Community Bank N.A. Sells 50 Shares of Amgen Inc. (NASDAQ:AMGN)” was posted by Daily Political and is owned by of Daily Political. If you are reading this article on another website, it was illegally copied and republished in violation of international trademark and copyright laws. The original version of this article can be read at https://www.dailypolitical.com/2017/07/19/community-bank-n-a-sells-50-shares-of-amgen-inc-nasdaqamgn.html.

A number of analysts recently commented on AMGN shares. Oppenheimer Holdings, Inc. set a $189.00 price objective on Amgen and gave the stock a “buy” rating in a research report on Tuesday, May 9th. Mizuho set a $195.00 price objective on Amgen and gave the stock a “buy” rating in a research report on Saturday, May 6th. Cowen and Company reiterated a “buy” rating and issued a $209.00 price objective on shares of Amgen in a research report on Thursday, April 27th. Vetr lowered Amgen from a “strong-buy” rating to a “buy” rating and set a $178.82 price objective for the company. in a research report on Monday, April 3rd. Finally, BMO Capital Markets reiterated a “buy” rating and issued a $198.00 price objective (down from $200.00) on shares of Amgen in a research report on Monday, May 22nd. One analyst has rated the stock with a sell rating, twelve have issued a hold rating, twelve have given a buy rating and three have assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $185.17.

In other Amgen news, SVP Cynthia M. Patton sold 2,922 shares of the stock in a transaction that occurred on Wednesday, May 24th. The stock was sold at an average price of $154.40, for a total value of $451,156.80. Following the transaction, the senior vice president now owns 24,214 shares in the company, valued at $3,738,641.60. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.20% of the stock is currently owned by corporate insiders.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.